UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

Future oncology (London, England), 2023-04, Vol.19 (11), p.737-738

2023

Link zum Volltext

Verfügbarkeit prüfen

Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome

Leukemia & lymphoma, 2006-04, Vol.47 (4), p.603-611

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma

Leukemia & lymphoma, 2019-03, Vol.60 (4), p.904-911

2019

Link zum Volltext

Verfügbarkeit prüfen

Isolated Central Nervous System Relapse in Aggressive Non-Hodgkin's Lymphoma: the Bologna Experience

Leukemia & lymphoma, 1999-01, Vol.32 (5-6), p.571-576

1999

Link zum Volltext

Verfügbarkeit prüfen

Clinical Features and Outcome in HCV-positive Aggressive Non-Hodgkin's Lymphoma

Leukemia & lymphoma, 2003-07, Vol.44 (7), p.1159-1164

2003

Link zum Volltext

Verfügbarkeit prüfen

Ifosfamide, Epirubicin and Etoposide (IEV) Regimen as Salvage and Mobilization Therapy for Refractory or Early Relapsing Patients with Aggressive Non-Hodgkin's Lymphoma

Leukemia & lymphoma, 2004-08, Vol.45 (8), p.1605-1609

2004

Link zum Volltext

Verfügbarkeit prüfen

Outcome of Elderly Patients with Aggressive Non-Hodgkin's Lymphoma Refractory to or Relapsing after First-line CHOP or CHOP-like Chemotherapy: A Low Probability of Cure

Leukemia & lymphoma, 2004-07, Vol.45 (7), p.1391-1394

2004

Link zum Volltext

Verfügbarkeit prüfen

Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma

Future oncology (London, England), 2016-08, Vol.12 (15), p.1759-1768

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review

Leukemia & lymphoma, 2019-06, Vol.60 (7), p.1610-1625

2019

Link zum Volltext

Verfügbarkeit prüfen

High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience

Leukemia & lymphoma, 2004-02, Vol.45 (2), p.321-326

2004

Link zum Volltext

Verfügbarkeit prüfen

Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

Expert opinion on pharmacotherapy, 2010-08, Vol.11 (11), p.1915-1923

2010

Link zum Volltext

Verfügbarkeit prüfen

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

Leukemia & lymphoma, 2010-09, Vol.51 (9), p.1668-1677

2010

Link zum Volltext

Verfügbarkeit prüfen

MACOP-B Chemotherapy for the Treatment of Aggressive Non Hodgkin's Lymphoma

Leukemia & lymphoma, 1992, Vol.6 (4-5), p.357-361

1992

Link zum Volltext

Verfügbarkeit prüfen

Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study

Leukemia & lymphoma, 2005-12, Vol.46 (12), p.1729-1734

2005

Link zum Volltext

Verfügbarkeit prüfen

Dexa-BEAM as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma

Leukemia & lymphoma, 2007-02, Vol.48 (2), p.349-356

2007

Link zum Volltext

Verfügbarkeit prüfen

Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment

Leukemia & lymphoma, 2006-08, Vol.47 (8), p.1535-1544

2006

Link zum Volltext

Verfügbarkeit prüfen

Hematopoietic stem cell transplantation in peripheral T-cell lymphomas

Leukemia & lymphoma, 2007-01, Vol.48 (8), p.1496-1501

2007

Link zum Volltext

Verfügbarkeit prüfen

FLUDAP: Salvage Chemotherapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

Leukemia & lymphoma, 2000, Vol.37 (3-4), p.309-317

2000

Link zum Volltext

Verfügbarkeit prüfen

Giant mesenteric fibromatosis associated with non-Hodgkin lymphoma. A case report and literature review

Acta chirurgica belgica, 2022-06, Vol.122 (3), p.204-210

2022

Link zum Volltext

Verfügbarkeit prüfen

Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma

Cancer investigation, 2016-07, Vol.34 (6), p.279-285

2016

Link zum Volltext

Verfügbarkeit prüfen

The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma

Leukemia & lymphoma, 2015-01, Vol.56 (1), p.12-25

2015

Link zum Volltext

Verfügbarkeit prüfen

Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Cancer investigation, 2006-01, Vol.24 (6), p.593-600

2006

Link zum Volltext

Verfügbarkeit prüfen

Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Leukemia & lymphoma, 2009-01, Vol.50 (3), p.380-386

2009

Link zum Volltext

Verfügbarkeit prüfen

The risk of CNS involvement in aggressive lymphomas in the rituximab era

Expert review of hematology, 2013-12, Vol.6 (6), p.643-652

2013

Link zum Volltext

Verfügbarkeit prüfen

Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma

Leukemia & lymphoma, 2005-10, Vol.46 (10), p.1477-1487

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Humans
(31)
Oncology
(31)
Hematology
(27)
Male
(25)
Female
(24)
Middle Aged
(24)
Adult
(21)
Lymphoma, Non-Hodgkin - Drug Therapy
(20)
Aged
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(17)
Prognosis
(12)
Treatment Outcome
(11)
Lymphoma, Non-Hodgkin - Mortality
(10)
Adolescent
(9)
Lymphoma, Non-Hodgkin - Therapy
(9)
Cyclophosphamide - Administration & Dosage
(8)
Doxorubicin - Administration & Dosage
(8)
Recurrence
(8)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Taylor & Francis Current Content Access
(36)
Taylor & Francis Journals Complete
(33)
MEDLINE
(31)
Journals@Ovid Complete
(5)
IngentaConnect Journals
(1)
EZB Electronic Journals Library
(1)
Ingenta
(1)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma

Isolated Central Nervous System Relapse in Aggressive Non-Hodgkin's Lymphoma: the Bologna Experience

Clinical Features and Outcome in HCV-positive Aggressive Non-Hodgkin's Lymphoma

Ifosfamide, Epirubicin and Etoposide (IEV) Regimen as Salvage and Mobilization Therapy for Refractory or Early Relapsing Patients with Aggressive Non-Hodgkin's Lymphoma

Outcome of Elderly Patients with Aggressive Non-Hodgkin's Lymphoma Refractory to or Relapsing after First-line CHOP or CHOP-like Chemotherapy: A Low Probability of Cure

Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma

Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review

High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience

Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

MACOP-B Chemotherapy for the Treatment of Aggressive Non Hodgkin's Lymphoma

Dexa-BEAM as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma

Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment

Hematopoietic stem cell transplantation in peripheral T-cell lymphomas

FLUDAP: Salvage Chemotherapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

Giant mesenteric fibromatosis associated with non-Hodgkin lymphoma. A case report and literature review

Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma

The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma

Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

The risk of CNS involvement in aggressive lymphomas in the rituximab era

Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma

Aktive Filter

Suchergebnisse filtern